Reviewing official pharmaceutical recall notices reveals an unsettling timeline: on September 27, 2019, health regulators posted a recall for Apo-Ranitidine 150mg F.C. Tablets. Nearly a month later, on October 18, a second recall was issued for Weidos Ranitidine F.C. Tablets 150mg and 300mg.
Both medications share identical therapeutic indications (treating acid reflux, benign gastric ulcers, and duodenal ulcers) and utilize the exact same active pharmaceutical ingredient (API): Ranitidine Hydrochloride.
Yet Horng Wey’s September notice cited “concerns regarding trace N-Nitrosodimethylamine (NDMA) impurities,” while Weidar’s October filing stated raw API materials contained “NDMA exceeding allowable intake limits.”
What Is NDMA?
N-Nitrosodimethylamine (NDMA) is a semi-volatile organic chemical categorized by the International Agency for Research on Cancer (IARC) as a Group 2A probable human carcinogen. Historically utilized in rocket fuels and antioxidants, it carries acute hepatotoxicity; sustained animal exposure demonstrates elevated liver neoplasm risks.
The European Medicines Agency (EMA) classifies NDMA under strict hazardous classifications: R45 (may cause cancer), R25 (toxic if swallowed), and R26 (very toxic by inhalation).
Regulatory Delays at the Taiwan Food and Drug Administration
Given the toxicological risks of NDMA, why did two domestic pharmaceutical formulations sharing the identical active ingredient have recall notices staggered nearly an entire month apart?
The European Medicines Agency (EMA) publicly announced safety reviews regarding NDMA detected in Ranitidine on September 13, 2019. This global alert prompted Horng Wey’s voluntary September filing.
Yet if the Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare, Republic of China (ROC), was aware of global alerts regarding Ranitidine APIs in mid-September, why did it take a month for another major manufacturer to announce recalls?
- If both companies sourced APIs from identical manufacturers, why did regulatory authorities fail to initiate proactive sweeps across all domestic Ranitidine formulations immediately?
- If they used different API sources, does this indicate wider systemic contamination across global raw material supplies?
In either case, waiting for individual manufacturers to “voluntarily report” rather than issuing mandatory regulatory recalls across the entire therapeutic category reflects reactive bureaucratic inertia. Drug safety regulators must prioritize public health over administrative passive compliance.
Support Independent Perspectives & In-Depth Insights
Every thoughtful analysis and candid critique comes from our dedication to truth and quality. We choose not to follow sensational algorithms or clickbait headlines.
Sustaining independent research requires reader support. Make a one-time or monthly contribution, securely processed by Google.
Payments secured by Google · Manage or cancel anytime in your Google Account



Comments